ArticleOxidative medicine and cellular longevity2026
New Mechanistic Insights Into Nobiletin's Protective Effects Against LPS-Induced Hyperinflammatory Acute Lung Injury in Rats: Targeting miR-200, AT1R/p38 MAPK, and HMGB1/NF-κB mTOR Pathways.
Article in Oxidative medicine and cellular longevity, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundAcute lung injury (ALI) and acute respiratory distress syndrome (ARDS) are severe inflammatory lung disorders associated with high morbidity and mortality. Dysregulation of the renin-angiotensin system (RAS) and proinflammatory pathways play an indispensable role in ALI progression.
aimThis study aimed to investigate the protective potential of nobiletin (NOB) in mitigating ALI and hyperinflammatory lung injury. MATERIAL AND
methodsThe study enrolled 32 male albino rats allocated into four groups: (Control, NOB, lipopolysaccharide [LPS], and NOB + LPS groups). Rats received NOB 20 mg/kg by oral gavage for 1 week; on the seventh day, a single dose of 15 mg/kg LPS was given by intranasal instillation. After 24 h of LPS administration, plasma and lung tissue samples were analyzed for inflammatory cytokines, mitochondrial complex-I, oxidative stress markers, and molecular signaling pathways.
resultsNOB administration significantly downregulated miR-200 expression, associated with ACE2 activation and attenuated AT1R-mediated inflammatory responses. It also decreased NF-κB and p38 MAPK signaling, reducing pulmonary and systemic levels of tumor necrosis factor-alpha (TNF-α), interleukin-6 (IL-6), granulocyte monocyte-colony stimulating factor (GM-CSF), and interleukin-17A (IL-17A). Additionally, NOB improved the high mobility group box 1 (HMGB1)/NF-κB/mammalian target of rapamycin (mTOR) pathway, and increased mitochondrial complex-I may be consistent with improved tissue preservation.
conclusionNOB exerts protective effects against ALI by improving inflammatory cytokine, oxidative stress, miRNA-200, mitochondrial complex-I, and ACE2, highlighting its potential as a protective candidate for ALI and hyperinflammatory-associated lung injury.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.